JD Health: GS Keeps Buy After the 15% Drop — Target Cut to HK$51

$6618.HK

GOLDMAN SACHS | LINCOLN KONG, RONALD KEUNG, LUQING ZHOU • 19 November 2026

1. Why did JD Health fall 15% — and why does Goldman Sachs call it overdone?

• Shares fell 15% on results day (19 November) after softer 4Q26 topline guidance — now double-digit % year over year — and worries about the 2027 growth outlook.

• Goldman Sachs calls the correction overdone: JD Health can still deliver low-teen % sales growth amid macro weakness and keep gaining share.

• Margin expansion stays intact on scale benefits and supply-chain management, with 20% core operating profit growth into 2027 after a 30% increase in 2026.

• The stock trades at 12x 2027E P/E, a historical low — ex-cash, just 3–4x forward P/E.

2. What actually happened in 3Q26 — revenue in line, profit a miss?

• Revenue rose 17% year over year, in line with expectations; adjusted operating profit rose 14% year over year, but 11% below Goldman Sachs' estimate.

• Adjusted operating margin slipped 0.1 percentage points year over year on front-loaded sales and marketing spending.

• By category: drugs grew 30%+ year over year, medical devices at a mid-single-digit % pace, nutrition at a high-single-digit % pace.

• Gross margin kept expanding on procurement scale and advertising monetization, despite ongoing price competition.

3. Why is 4Q26 set to slow — nutrition, flu, or both?

• Management guides 4Q26 revenue growth at double-digit % year over year: drugs 20–25%, medical devices mid-single-digit %, nutrition low-single-digit %.

• Nutrition weakened again in 4Q26 after news flow around leading brands dented consumer confidence; management calls it temporary and still sees share gains in the category.

• The flu season is materially weaker than in 4Q25 — flu periods also drive platform traffic and chronic-disease demand, not just flu-drug sales.

• Growth is expected to re-accelerate from 1Q27 as nutrition recovers and drug momentum holds.

4. What changed in the forecasts — and what should investors watch?

• The 12-month target price was cut to HK$51 from HK$59; the target multiple fell to 18x (from 22x) on slower topline growth and peer de-rating. Buy is kept.

• 2026E–28E revenue estimates were cut 2–4%; net profit estimates cut 2–6%.

• FY26 profit guidance is unchanged: non-IFRS operating profit +30% year over year; 2027 profit growth is expected to outpace revenue growth.

• Watch next: the buyback continues and dividends are increasingly likely, with Hong Kong tax residency secured; risks are slower 2027 sales, margin pressure from delivery, offline and AI investment, and competition from online pharmacy, O2O and livestreaming e-commerce.

#JDHealth #OnlinePharmacy #ChinaStocks #Healthcare #Ecommerce

Source: Goldman Sachs, 19 November 2026. Based solely on the report provided; forecasts are not guaranteed. For reference only; not investment advice.

Read the full breakdown on Unhidea: https://unhidea.com/en/articles/research-50fbe9820c7c4f99964198039c666fb8-en

Visit unhidea.com for more of the latest sell-side research interpretations.